Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies

Page 4 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.

• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' ExpressionCompletedNCT03480360Phase 3Results posted
• A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03462719Phase 3Results posted
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesCompletedNCT03448393Phase 1Results posted
• A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination TherapyCompletedNCT03406156Phase 3Results posted
• VAY736 in Combination With Ibrutinib in Patients With CLL on IbrutinibTerminatedNCT03400176Phase 1Results posted
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLActive, not recruitingNCT03336333Phase 3Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasActive, not recruitingNCT03277729Phase 1/2Results posted
• Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
• Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)CompletedNCT03207555Phase 2Results posted
• Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03206918Phase 2Results posted
• Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03204188Phase 2Results posted
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaTerminatedNCT03195010Phase 2Results posted
• A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p DeletionCompletedNCT03190330Phase 4Results posted
• Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived MalignanciesTerminatedNCT03151057Phase 1Results posted
• 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell TransplantationCompletedNCT03133221Phase 2Results posted
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesCompletedNCT03088878Phase 1/2Results posted
• A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's LymphomaCompletedNCT03078855Phase 3Results posted
• Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesCompletedNCT03056339Phase 1/2Results posted
• Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLCompletedNCT03045328Phase 2Results posted
• Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03041636Phase 2Results posted
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
• Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B CellCompletedNCT03019055Phase 1Results posted
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaCompletedNCT03010358Phase 1/2Results posted
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
• Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02983617Phase 2Results posted
• A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).CompletedNCT02980731Phase 3Results posted
• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingNCT02970318Phase 3Results posted
• Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT02968563Phase 2Results posted
• BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaCompletedNCT02933320Phase 1/2Results posted
• Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT02910583Phase 2Results posted
• Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsTerminatedNCT02877082Phase 2Results posted
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantCompletedNCT02869633Phase 2Results posted
• Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961CompletedNCT02860676Phase 1Results posted
• A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02801578Phase 2/3Results posted
• HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation CyclophosphamideCompletedNCT02793544Phase 2Results posted
• Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLLTerminatedNCT02784834Phase 1Results posted
• Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and RecoveryCompletedNCT02767388Results posted
• Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With IbrutinibCompletedNCT02759016Phase 1Results posted
• A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02756611Phase 3Results posted
• Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTerminatedNCT02742090Phase 2Results posted
• A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT02733042Phase 1/2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyActive, not recruitingNCT02717611Phase 2Results posted
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesTerminatedNCT02706392Phase 1Results posted
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedNCT02656303Phase 2Results posted
• Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line TherapyCompletedNCT02649387Phase 2Results posted
• Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKiCompletedNCT02639910Phase 2Results posted
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3Results posted
• A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaCompletedNCT02594384Phase 1Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)Active, not recruitingNCT02586857Phase 1/2Results posted
• Reduced Intensity Conditioning Transplant Using Haploidentical DonorsCompletedNCT02581007Phase 2Results posted
• Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLTerminatedNCT02557516Phase 1/2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D DeficiencyCompletedNCT02553447Not applicableResults posted
• Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic LeukemiaTerminatedNCT02538614Phase 1Results posted
• A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT02537613Phase 1Results posted
• A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02533401Phase 2Results posted
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT02530515Phase 2Results posted
• A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLLActive, not recruitingNCT02514083Phase 2Results posted
• Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell TransplantActive, not recruitingNCT02506933Phase 2Results posted
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsCompletedNCT02481297Phase 2Results posted
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT02477696Phase 3Results posted
• Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLActive, not recruitingNCT02475681Phase 3Results posted
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
• Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT02427451Phase 1/2Results posted
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or LymphomaCompletedNCT02424968Phase 2Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02406742Phase 1/2Results posted
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT02396134Phase 2Results posted
• QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabTerminatedNCT02384954Phase 1/2Results posted
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLTerminatedNCT02361346Phase 1/2Results posted
• Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic LeukemiaCompletedNCT02340780Phase 2Results posted
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
• Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
• Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
• A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT02320487Phase 2Results posted
• Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.CompletedNCT02315768Phase 1/2Results posted
• Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell LymphocytosisTerminatedNCT02309515Phase 2Results posted
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin LymphomaCompletedNCT02303392Phase 1Results posted
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)CompletedNCT02301156Phase 3Results posted
• A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedNCT02268851Phase 1Results posted
• A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)CompletedNCT02264574Phase 3Results posted
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaTerminatedNCT02258529Phase 2Results posted
• Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedNCT02257242Phase 1Results posted
• A Phase I/II Study of Intratumoral Injection of SD-101CompletedNCT02254772Phase 1/2Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic LeukemiaCompletedNCT02242942Phase 3Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
• Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT02225275Phase 2Results posted
• UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT02222688Phase 1Results posted
• Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasCompletedNCT02213913Phase 1/2Results posted
• Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)CompletedNCT02208037Phase 2Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor TherapyCompletedNCT02141282Phase 2Results posted

← Leukemia, Lymphocytic, Chronic, B-Cell overview